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Summary. This article focuses on statistical implications of proportional
rate models for recurrent event data in the presence of a terminal event. In
such circumstances, various definitions of the recurrent rate function have
been adopted in the proportional rate models. Although these rate functions have quite different interpretations, recognition of the differences has
been lacking theoretically and practically. We compare three types of rate
functions from both conceptual and quantitative perspectives; conclude that
the inappropriate choice of a rate function may lead to misleading scientific
conclusions. Simulations are conducted for comparisons of the focused models. Analysis of data from an AIDS clinical trial is presented to illustrate the
analytical results.
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tion.
1.

Introduction

In many longitudinal follow-up studies, recurrent events are recorded as
outcome measurements where the occurrence of recurrent events could be
stopped by a terminal event, such as death. For instance, recurrences of
hospitalizations could be terminated by the death of a patient; repeated opportunistic infections could be terminated by death. The terminal event is
usually not independent of the recurrent events. Hence, treating the terminal event as a part of an independent censoring mechanism is not generally
appropriate. If the terminal event is of interest besides the recurrent events,
a joint model for the recurrent and terminal events could be considered, otherwise the terminal event can be treated as a nuisance and explicit modelling
of the terminal event can be avoided.
In the absence of a terminal event, the regression methods for recurrent
events were studied in the important articles of Prentice, Williams and Peterson (1981), and Anderson and Gill (1982). Both articles studied intensity
models which serve as proper predictive models in applications. However,
to identify treatment effects or risk factors, marginal rate models would be
more preferable by practitioners. Marginal rate models were considered by
Pepe and Cai (1993), and Lin, Wei, Yang and Ying (2000), and independent
censoring was still assumed as that in the intensity models. From the viewpoint of applications, the independent censoring assumption is reasonable
in intensity models since censoring could be largely explained by event history and covariates, but more restrictive in the marginal rate models. With
the intention to deal with dependent censoring in a marginal model, Wang,
2
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Qin and Chiang (2001) proposed a nonparametric one-sample method and a
semiparametric regression model for the recurrent events.
In the presence of a terminal event, one-sample methods, proposed by
Cook and Lawless (1997), Ghosh and Lin (2000), and Wang, Qin and Chiang (2001), can be used to estimate the recurrent rate functions. Abundant
regression approaches fall into several categories according to the inference
of interest: Cook and Lawless (1997), Ghosh and Lin (2002), Huang and
Wang (2004), Liu, Wolfe and Huang (2004), and Schaubel and Cai (2005)
assumed proportional rate models for recurrent events; Ghosh and Lin (2003)
proposed an accelerated failure time model for recurrent events, where the
effect of covariates was directly on recurrent event times; Huang and Wang
(2003) proposed joint models of the recurrent and terminal events, where the
inference was focused on the frequency of recurrent events at the failure time
of the terminal event. In the literature of the proportional rate models, we
found that different definitions of rate function have been adopted for modelling recurrent event processes. However, implications of these rate models
can be quite different or even conflicting with each other. In this article we
present careful comparison of these proportional rate models and point out
that inappropriate choice of a rate function may lead to misleading scientific results. We further provide guidance for choosing appropriate statistical
models and interpreting analytical results. Our focus is on the rate functions
and their subtle interrelationships throughout.
The rest of the article is organized as follows. In Section 2, the proportional rate models based on three different rate functions are studied in
both conceptual and practical perspectives. Quantitative comparisons of the
3
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focused models are presented in Section 3. A simulation study and the analysis of a data from an AIDS clinical trial are reported in Section 4. Some
concluding remarks follow in Section 5.
2.

Rate Functions and Proportional Rate Models

The proportional rate models are commonly used for analyzing recurrent
event data in the presence or absence of an explicit terminal event. When
a terminal event is present, various definitions of the rate function for a
recurrent event process have been adopted in the proportional rate models.
It is important to identify the distinctions of these rate functions, on which
the interpretation of regression parameters is based. We will devote this
section to introducing three distinct rate functions and their corresponding
regression models.
2.1 The Rate Function
Let N (t) denote the number of recurrent events occurring at or before time t,
t ≥ 0, and D, the time to the terminal event, where N (t) and D are possibly
correlated. The rate function, which is the occurrence rate of recurrent events
over a time interval, is defined as
λ(t) = lim+
∆t→0

Pr(N (t + ∆t) − N (t) > 0)
,
∆t

t ∈ [0, τ ].

(1)

Assuming that lim∆t→0+ Pr(N (t + ∆t) − N (t) > 1) = 0, we have λ(t)dt =
Rt
E[dN (t)]. Further we define the cumulative rate function as Λ(t) = 0 λ(u)du,
which is equal to E[N (t)]. A non-parametric method for estimating the cumulative rate function was proposed by Wang, Qin and Chiang (2001).
This rate function is of great interest in randomized clinical trials because
4
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of the fact that the population of this rate function is determined at time
origin 0 for any t ≥ 0. Since randomization is typically performed at time
0, the populations of the rate functions for different treatments are always
comparable to each other at any t ≥ 0. In the presence of a terminal event,
e.g. death, we notice that the recurrent event process and the rate function after death are mathematically well defined, but latent in reality due
to the fact that the recurrent event process after death does not exist. The
rate function has a marginal interpretation, which is desirable for studying
population-average treatment effects. However, by directly modelling the
marginal rate function, it would be difficult to characterize the correlation
between the recurrent event process and the terminal event. With the intention to deal with the dependence between the terminal and the recurrent
events, Huang and Wang (2004) proposed a joint model. In their approach,
conditioning on a latent variable Z, the recurrent and terminal events were
modelled separately as two subject-specific models, with the correlation characterized by Z. The latent variable Z can be considered as, say, the latent
health status of a patient. A brief review of the three assumptions (A1),
(A2), and (A3) for this model is given as follows:
(A1) Let X be a 1 × p vector of covariates and x be the realization of
X. There exists a nonnegative-valued latent variable Z so that, given
X = x and Z = z, the recurrent event process N (·) is a nonstationary
Poisson process with intensity function
λ(t|x, z) = zλ0 (t) exp(xβ),

0 ≤ t ≤ τ,

(2)

where β is a p × 1 vector of parameters and the baseline intensity
5
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function λ0 (t) is a continuous function with the constraint Λ0 (τ ) =
Rτ
λ0 (u)du = 1. Research interest is within a fixed time interval [0, τ ].
0
The latent variable Z satisfies E[Z|X] = E[Z].
(A2) Given (x, z), the hazard function of D has the form
h(t|x, z) = zh0 (t) exp(xα),

(3)

where α is a p×1 vector of parameters and the baseline hazard function
h0 (t) is continuous.
(A3) Conditioning on (x, z), (N (·), D) are mutually independent.
Conditioning on z, the intensity function is also the rate function since a
Poisson process is memoryless. When integrating out Z, one has the marginal
rate function at time t for subjects with covariate x,
λ(t|x) = µZ λ0 (t) exp(xβ),

(4)

where µZ = E[Z].
Assumption (A3) applies to (N (t), D) for t before and after the time
of the terminal event, D. Here, the model structure of the latent part,
{(N (t), D) : t > D}, should be considered only as a “working assumption”,
which is assumed for ease of establishing statistical properties. In reality,
to use model (A1-3), it is necessary to validate the model assumptions only
for those t ≤ D. Through the unobserved z and observed covariate x, the
correlation between a patient’s recurrent event process and terminal event
is explained. In other words, after controlling z and x on a patient, the
recurrent event process and the terminal event are operating independently.
6
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In this model, both the recurrent event model (in A1) and the terminal
event model (in A2) have subject-specific interpretation for the regression
coefficients. Also, the parameter β can be interpreted marginally, given the
relationship in (4). Suppose X is a dichotomous treatment indicator, i.e.
X = 1 indicates the treatment and X = 0 the control group, the interpretation of eβ would be the ratio of the occurrence rate of recurrent events
for the treatment group to that for the control group at a patient’s level.
The interpretation of the regression coefficient for the recurrent events, β, is
not affected by the terminal event. In contrast, we will see that the other
two rate functions involve both the recurrent event process and the terminal
event. Model (A1-3) will be used as our core model. Its relationship with
models based on the other two rate functions will be discussed in Section 3.
2.2 The Adjusted Rate Function
The second rate function, termed as the adjusted rate function, is based on
the observed counting process N ∗ (t):
½
N (t)
if t < D,
∗
N (t) =
N (D)
if t ≥ D.
R
t
Equivalently, N ∗ (t) = 0 I(D ≥ u)dN (u), where I(·) is an indicator function.
The adjusted rate function, λA (t), is hence defined as
λA (t)dt = E[dN ∗ (t)] = E [I(D ≥ t)dN (t)] .

(5)

The corresponding cumulative rate function is ΛA (t) = E[N ∗ (t)]. It follows
from N ∗ (t) ≤ N (t) that λA (t) ≤ λ(t), t ∈ [0, τ ]. In some studies, the treatment effects are present in both the recurrent and terminal events under the
core model (A1-3). However, the two effects can potentially result in the adjusted rate function in the opposite direction from a given rate function. For
7
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example, patients in a later stage of AIDS suffer more frequent opportunistic
infections than patients in an earlier stage, which corresponds to an increasing rate function in (1). However, after adjusting for the presence of deaths,
we could observe a decreasing adjusted rate function. This might lead to a
wrong impression that AIDS patients experience less frequent infections later
than earlier. It can be seen from this example that the adjusted rate function
is not appropriate for describing natural history of opportunistic infections.
The adjusted rate function could, say, be useful for insurance companies to
study the medical cost associated repeated hospitalizations, where the adjustment is needed because medical cost vanishes after one’s death. From
the standpoint of insurance companies, expense rather than patients’ disease
progression is the focus of interest.
The proportional rate model based on the adjusted rate function is
A
λA (t|x) = λA
0 (t) exp(xβ ),

(6)

A
where λA
0 (t) is the baseline function and β is a p × 1 vector of regression co-

efficients. See Ghosh and Lin (2002) for related work. Modeling the adjusted
rate function based on the observed counting process is convenient since no
assumption is needed for the recurrent event process after the terminal event.
While the use of this model is relevant and interesting for some studies, in a
clinical trial setting, the interpretation of the regression coefficients could be
misleading because the adjusted rate function involves both recurrent and
terminal events in a complicated manner. Consequently, a negative value
of β A in (6) does not necessarily imply a truly beneficial effect on recurrent
events, in the same way, a positive value of β A does not necessarily imply a
harmful effect.
8
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[Figure 1 about here.]
It is not difficult to find a situation in which the adjusted rate ratio does
not retain the rate ratio. Suppose a new drug prolongs one’s lifetime [Figure
1(a)] while it makes no difference in the occurrences of recurrent diseases, as
compared with an existing drug [Figure 1(b)]. In this scenario, it is likely to
observe more disease occurrences in patients receiving the new drug because
they live longer than patients receiving the existing drug. This explains why
the adjusted rate function is larger in the new drug group than that in the
existing drug group [Figure 1(c)]. In this case, the new, life-saving drug is
seen to be accompanied with higher frequencies of disease occurrences by the
misleading result from comparing the adjusted rate functions.
Based on the previous discussion, it seems that, applying the adjusted
rate model in (6) on clinical trials to study the treatment effect on the occurrences of recurrent events, is not generally appropriate. More quantitative
discussion will be made in Section 3 to demonstrate the different situations
where we can and cannot use the adjusted rate model.
2.3 The Survivors’ Rate Function
Making inference on recurrent event processes for patients who are currently
alive is of interest in many studies (Schaubel and Cai, 2005; Liu, Wolfe and
Huang, 2004). The third rate function, λS (t), termed as the survivors’ rate
function, is the recurrence rate among survivors:
λS (t)dt = E[dN (t)|D ≥ t].

(7)

The corresponding cumulative rate function among survivors is ΛS (t) =
Rt S
λ (u)du. When the recurrent and terminal event processes are indepen0
9
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dent, we have λS (t) = λ(t). We note that λS (t) = λA (t)/Pr(D ≥ t), which
implies λS (t) ≥ λA (t). It should be noted that the population for defining
the survivors’ rate function changes with time. Explicitly, the defining population could only be randomized at baseline, i.e., t = 0. After time 0, this
rate function is defined for unrandomly selected subpopulation, the survivors.
Therefore, the survivors’ rate function should be used with caution in randomized trials when the terminal event is not independent of the recurrent
events.
The proportional rate model based on the survivors’ rate function takes
the form,
λS (t|x) = λS0 (t) exp(xβ S ),

(8)

where λS0 (t) is the baseline function and β S is a p × 1 vector of regression
coefficients. Similar to the adjusted rate model, the survivors’ rate model
technically circumvents modeling recurrent event process after death. However, an informative terminal event can potentially confound the interpretation of β S . This is because, when the terminal event is informative for the
recurrent event process, β S carries information of the treatment effects from
both the recurrent and terminal events. In contrast, from the standpoint of
clinical investigation, the core model singles out the treatment effect on the
recurrent diseases besides the treatment effect on survival. More details of
model comparisons will be discussed in the next section.
A summary of the three focused rate functions and the corresponding
proportional rate models is listed in Table 1. It should be noted that the
statistical inferences of the three discussed models are all valid under their
10
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own model assumptions. The focus of this paper is on the differences of their
interpretations or implications.
[Table 1 about here.]

3.

Quantitative Comparison of Models

We have seen that both the adjusted rate model and the survivors’ rate
model have their own limitations in a clinical trial setting, with or without
the core model assumptions (A1-3). However, for ease of discussion, we use
the core model as a frame of reference to investigate implications of the other
two proportional rate models under the core model’s assumptions. We will
assume that X is a treatment indicator and the only covariate throughout
this section.
3.1 The Adjusted Rate Model under the Core Model Assumptions
We first investigate the adjusted rate function, with the notion that the core
model assumptions are correct. We have
λA (t|x)dt = E[I(D ≥ t)dN (t)|x]
= E[E[I(D ≥ t)dN (t)|Z, X]|x]
= E[Pr(D ≥ t|Z, X) · E[dN (t)|Z, X]|x]
¯ ¸
·
½ Z t
¾
¯
= E exp −
Zh0 (u) exp(xα)du · Zλ0 (t) exp(xβ)dt¯¯ x
0

= λ0 (t) exp(xβ)E[Z exp{−Z exp(xα)H0 (t)}|x]dt,
where H0 (t) =

Rt
0

(9)

h0 (u)du is the cumulative baseline hazard function for time

to the terminal event in (A2). In general, the adjusted rates for different x
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values are not proportional to each other, i.e., rate ratios depend on t. The
adjusted rate ratio for the treatment compared with the control group is
·
½
¾¸
λA (t|x = 1)
E[Z exp{−Zeα H0 (t)}]
= exp β + log
,
λA (t|x = 0)
E[Z exp{−ZH0 (t)}]

(10)

which is not functionally independent of t. The adjusted rate functions for
the treatment and control groups have a crossover at t whenever t satisfies
eβ =

E[Z exp(−ZH0 (t))]
.
E[Z exp(−Zeα H0 (t))]

The adjusted rate ratio in (10) is determined by four elements: β, α, H0 (t),
and the distribution of Z. It is obvious that λ0 (t) does not affect the ratio
whatsoever, though it does affect the absolute magnitude of the rate.
We next examine how the relationship of α and β affects the adjusted rate
ratio leaving the other elements unchanged and assuming that Pr(Z > 0) > 0
and H0 (t) > 0.
Scenario I: β = 0 and α 6= 0
In this situation, the treatment does not affect the recurrent events, but it
affects the terminal event. If α < 0, λA (t|x = 1) > λA (t|x = 0); if α > 0,
λA (t|x = 1) < λA (t|x = 0). In either case, by comparing the adjusted rates,
we could “observe” an effect of X on the recurrent events which actually
does not exist. As we have seen, different directions of the effect on the
terminal event yield false effects in different directions on the recurrent events.
Modeling the adjusted rate is not appropriate for examining the treatment
effect on the recurrent events in this scenario.

12
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Scenario II: αβ > 0
This means that the treatment effects on the recurrent and terminal events
have the same direction. For example, when the recurrent and terminal
events are both adverse events, αβ > 0 means the treatment is either beneficial (α < 0, β < 0) or harmful (α > 0, β > 0) for both events. In such
circumstances, β and log{E[Z exp{−Zeα H0 (t)}]/E[Z exp{−ZH0 (t)}]} have
opposite signs, which means that the existence of treatment effect on the terminal event (α 6= 0) attenuates the adjusted rate ratio from the underlying
rate ratio. The attenuation can lead to adjusted rate ratio in an opposite
direction from the rate ratio. In addition, considering the nonproportionality and possible crossovers between the adjusted rate functions, the adjusted
rate model is not applicable in this scenario.
Scenario III: αβ < 0
Consider the situation that the treatment effects on the recurrent and terminal events are in opposite directions. For example, a drug can decrease the
frequency of repeated opportunistic infections in AIDS patients, but increase
the risk of death at the same time. We notice that β and log {E[Z exp{−Zeα H0 (t)}]/
E[Z exp{−ZH0 (t)}]} have the same sign here, which means no crossover
could occur between λA (t|x = 0) and λA (t|x = 1). However, α inflates the
adjusted rate ratio from the underlying rate ratio. Hence, the adjusted rate
model does not apply in this scenario.
Scenario IV: β 6= 0 and α = 0
In this case, the adjusted rate degenerates to λ0 (t)E[Z exp{−ZH0 (t)}] exp(xβ).
Define the product of the first two terms as λA
0 (t) = λ0 (t)E[Z exp{−ZH0 (t)}],

13
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which becomes the new baseline rate function, then the adjusted rate funcβ
tion has the form λA (t|x) = λA
0 (t) exp(xβ). We can see that e could either be

interpreted as the rate ratio coming from the core model, or as the adjusted
rate ratio. This means that the proportional rate model can be applied to
correctly identify the treatment effect on the recurrent events even though
the absolute magnitude of λA (t|x) is biased from λ(t|x). The bias term
−1
A
is µ−1
Z E[Z exp{−ZH0 (t)}], since λ (t|x) = λ(t|x)µZ E[Z exp{−ZH0 (t)}],

where λ(t|x) = µZ λ0 (t) exp(xβ).
Scenario V: N (t) and D are independent for given x
Now we consider the situation where the recurrent and terminal event processes are conditionally independent within each treatment group. Under the
core model’s assumptions, the adjusted rate for given x is λ0 (t) exp(xβ)µZ
exp{−µZ exp(xα)H0 (t)} and the adjusted rate ratio, λA (t|x = 1)/λA (t|x =
0) = exp{β − µZ H0 (t)(eα − 1)}. We find that under the conditional independence condition, the adjusted rate ratio could be attenuated or inflated from
the underlying rate ratio when different combinations of α and β present,
as we discussed in Scenarios I-IV. After adjusting for death, the adjusted
functions distort the underlying rate functions and may be misleading when
it is used to examine the treatment effect on the recurrent events, no matter
whether the recurrent and terminal event processes are independent or not.
3.2 The Survivors’ Rate Model under the Core Model Assumptions
Assuming that the core model in (A1-3) is correct, the survivors’ rate function
is:

14
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λS (t|x)dt = E[dN (t)|D ≥ t, x]
= E[E[dN (t)|D ≥ t, Z, X]|D ≥ t, x]
= E[E[dN (t)|Z, X]|D ≥ t, x]
= E[Zλ0 (t) exp(xβ)dt|D ≥ t, x]
= λ0 (t) exp(xβ)E[Z|D ≥ t, x]dt,

(11)

where
E[ZPr(D ≥ t|Z, X)|x]
Pr(D ≥ t|x)
E[Z exp{−Z exp(xα)H0 (t)}|x]
=
.
E[exp{−Z exp(xα)H0 (t)}|x]

E[Z|D ≥ t, x] =

(12)

The third equality in (11) follows from Assumption (A3). We prove in the
Appendix that E[Z|D ≥ t, x = 1] ≥ E[Z|D ≥ t, x = 0] when α < 0;
E[Z|D ≥ t, x = 1] ≤ E[Z|D ≥ t, x = 0] when α > 0. The survivors’ rate
ratio for the treatment group to the control group is
·
½
¾¸
λS (t|x = 1)
E[Z|D ≥ t, x = 1]
= exp β + log
,
λS (t|x = 0)
E[Z|D ≥ t, x = 0]
which is not functionally independent of t. The survivors’ rate functions for
the two treatment groups have a crossover at t whenever t satisfies
eβ =

E[Z|D ≥ t, x = 0]
.
E[Z|D ≥ t, x = 1]

We now examine how different combinations of α and β (in Scenarios
I-IV) affect the survivors’ rate ratio when the recurrent and terminal event
processes are possibly correlated within each treatment group.
15
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Scenario I: β = 0 and α 6= 0
If α < 0 and β = 0, λS (t|x = 1) > λS (t|x = 0); and if α > 0 and β = 0,
λS (t|x = 1) < λS (t|x = 0). Through the comparison of the survivors’ rate
functions, a false treatment effect on the recurrent events would be observed,
it, however, does not actually exist.
Scenario II: αβ > 0
When α < 0 and β < 0, we have proved that E[Z|D ≥ t, x = 1] ≥ E[Z|D ≥
t, x = 0]. This is intuitive, because the treatment prolongs patients’ lifetime
so that the survivors at time t in the treatment group are more fragile than the
survivors in the control group. By “more fragile” we mean a larger expected
value of the latent variable Z. Hence, log{E[Z|D ≥ t, x = 1]/E[Z|D ≥
t, x = 0]} ≥ 0. Similarly, when α > 0 and β > 0, log{E[Z|D ≥ t, x =
1]/E[Z|D ≥ t, x = 0]} ≤ 0. In either case, β and log{E[Z|D ≥ t, x =
1]/E[Z|D ≥ t, x = 0]} have opposite signs, which means that the survivors’
rate ratio is attenuated from the underlying rate ratio. The attenuation can
lead to a survivors’ rate ratio in an opposite direction from the underlying rate
ratio. In addition, the survivors’ rate functions for the treatment and control
groups are not proportional. The survivors’ rate model is not applicable in
this scenario.
Scenario III: αβ < 0
By a similar argument as that in Scenario II, it can be seen that β and
log{E[Z|D ≥ t, x = 1]/E[Z|D ≥ t, x = 0]} have the same sign in this
scenario. Accordingly the survivors’ rate ratio always has the same direction
as the rate ratio. However, the existence of the treatment effect on the

16
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terminal event, α, inflates the survivors’ rate ratio from the underlying rate
ratio, and also causes the nonproportionality of the survivors’ rates between
the two treatment groups. Again, the proportional rate model using the
survivors’ rate function does not work in this scenario.
Scenario IV: β 6= 0 and α = 0
When the treatment has no effect on the terminal event, it can be seen from
(12) that
E[Z|D ≥ t, x = 1] = E[Z|D ≥ t, x = 0] =

E[Z exp{−ZH0 (t)}]
.
E[exp{−ZH0 (t)}]

It means that the survivors at time t in the treatment and the control groups
are comparable, in terms of the average latent health status. Hence, λS (t|x =
1)/λS (t|x = 0) = eβ . Here, eβ could be seen either as the rate ratio from
the core model, or as the survivors’ rate ratio. Consequently, the survivors’
rate model can be applied to correctly identify the treatment effect on the
recurrent events in this scenario. Here λS (t) is different from λ(t) by a factor,
µ−1
Z E[Z|D ≥ t].
Scenario V: N (t) and D are independent for given x
When the recurrent and terminal event processes are independent within
each treatment group, the survivors’ rate function λS (t|x) equals the rate
function λ(t|x). In such situation, modelling the survivors’ rate is equivalent
to modelling the rate function. It should be noted that this equivalence does
not rely on the assumptions of the core model.

17
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4.

Simulations and A Data Analysis

4.1 Simulations
We examine the appropriateness of the proportional rate model for the
adjusted rate and the survivors’ rate under the core model. Assume Z follows
a gamma distribution with mean 10 and variance 50, λ0 (t) = 1/10, and
h0 (t) = t/400. X is the treatment indicator, where X = 1 corresponds to
treatment and X = 0 control group. The adjusted rate function has the
explicit form
·
¸−3
1 2
1
1
exp(xβ)
t exp(xα) +
,
λ (t|x) =
125
800
5
A

and the survivors’ rate function is
·
¸−1
1 2
1
1
exp(xβ)
t exp(xα) +
.
λ (t|x) =
5
800
5
S

[Figure 2 about here.]
[Figure 3 about here.]
Figures 2 and 3 give the adjusted rate functions and the survivors’ rate
functions with different combinations of (α, β) respectively, with their corresponding log rate ratios. The simulation results confirm the theoretical
comparisons we discussed in the previous sections. We also observe that,
when the magnitude of the treatment effect on the terminal event is smaller
than that on the recurrent events, the violation of proportionality in the adjusted or the survivors’ rate functions is less sever, i.e., the adjusted or the
survivors’ rate ratio is closer to a constant. When the treatment has no effect
on the terminal event, the β-values of the three discussed proportional rate
18
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models all represent the same quantity one is trying to estimate, log rate
ratio, which is the treatment effect on the recurrent events.
4.2 Data Analysis
Now we compare three rate functions using the data from the Terry
Beirn Community Programs for Clinical Research on AIDS (CPCRA) didanosine/zalcitabine trial. This clinical trial aimed to compare two treatments, didanosine (ddI) and zalcitabine (ddC), for patients who previously
received zidovudine and had 300 or fewer CD4 cells per cubic millimeter or
a diagnosis of AIDS (Abrams et al., 1994). A focused interest was the comparison of the survival time and the clinical disease progression for the two
treatment arms. Clinical disease progression was defined as the occurrence of
certain recurrent diseases from a class of AIDS-defining conditions and some
opportunistic diseases (Abrams et al., 1994). This randomized trial assigned
230 patients to receive ddI and 237 to receive ddC. During the follow-up
time with the median length 16 months, 100 deaths were recorded in the ddI
group and 88 in the ddC group. One hundred twenty of the patients taking
ddI experienced a total count of 172 recurrent diseases and 115 taking ddC
experienced 191 recurrent diseases.
To compare the survival for the two treatments we plot the Kaplan-Meier
estimate of the survival function for both ddI and ddC groups in Figure 4. It
confirms that ddC may have provided survival advantage over ddI (Abrams
et al., 1994). However, during the first 6 months of follow-up, the survival of
patients in the two treatment groups was virtually the same.
In order to examine the treatment effect on clinical disease progression,
the following three one-sample methods, the estimation of the cumulative
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rate function (Wang et al., 2001), the estimation of the adjusted cumulative
rate function (Ghosh and Lin, 2000; Cook and Lawless, 2002), and the estimation of the survivors’ cumulative rate function (Cook and Lawless, 1997)
are applied. The resulting estimates for both treatment arms are shown in
Figure 5.
The estimates of the cumulative rate function in Figure 5(a) show that
the estimated cumulative rate of the recurrent diseases for both treatment
arms were not significantly different in the middle of the follow-up period
(month 8 to month 12). Before month 8, the ddC group had a slightly
bigger cumulative rate than the ddI group and after month 12, the ddC
group had a smaller cumulative rate than the ddI group. The 95% pointwise Bootstrap confidence bands for the two treatments (not shown) were
explored, which overlapped in the first 16 months of follow up, however,
showed a significant difference after the 16th month. Therefore, ddC was
shown to be more efficacious than, or at least as efficacious as, ddI in delaying
disease progression since the 8th month after randomization.
Now we examine the adjusted cumulative rate functions for both treatments in Figure 5(b) and the the survivors’ cumulative rate functions in
Figure 5(c). It is found that during the first 6 months of follow-up, all three
kinds of function estimate give a consistent result that the cumulative rate
(or the adjusted cumulative rate, or the survivors’ cumulative rate) for the
ddC group is slightly bigger than for the ddI group. This is because the
two treatments didn’t work differently on survival during the first 6 months
after randomization (see Figure 4). A remarkable difference between the estimated cumulative rate functions and the estimated adjusted or survivors’
20
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cumulative rate functions appeared after month 6, when both the adjusted
and the survivors’ cumulative rates showed a “beneficial” effect of ddI over
ddC. This confirms our discussion made earlier that the survival difference
between the two treatments can attenuate the adjusted and survivors’ rate
ratio from the underlying rate ratio, or even reverse their directions from the
underlying rate ratio. It should be noticed that both the estimated adjusted
and survivors’ cumulative rate functions were smaller than the estimated cumulative rate function, with the estimated adjusted cumulative rate function
even smaller than the survivors’ one.
[Figure 4 about here.]
[Figure 5 about here.]

5.

Discussion

In clinical trials, it is not uncommon that the follow-up of a patient is stopped
by the occurrence of a terminal event. In this situation the assessment of a
treatment or a risk factor using recurrent events is likely to be confounded by
the presence of the terminal event. Similar situations exist in other data settings, such as competing risk data, where the occurrence of one type of event
can preclude the occurrence of the other types of events. In these circumstances, choosing appropriate models is necessary and critical for the correct
interpretation of the data. In this paper, we compared three proportional
rate models for recurrent event data in the presence of a terminal event. The
behaviors of the discussed models, as well as the appropriateness of assuming
these models, under different situations were investigated. We showed that
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the inappropriate choice of a model may lead to misleading scientific results
in various situations.
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Appendix
We now prove that for a univariate real-valued covariate X, E[Z|D ≥ t, x]
is monotonic in x under the core model assumptions. We first consider the
partial derivative of E[Z|D ≥ t, x] with respect to x:
∂
E[Z|D ≥ t, x]
∂x µ
¶
∂ E[Z exp{−Z exp(xα)H0 (t)}|x]
=
∂x
E[exp{−Z exp(xα)H0 (t)}|x]
= α exp(xα)H0 (t){E 2 [Z exp{−Z exp(xα)H0 (t)}]
−E[Z 2 exp{−Z exp(xα)H0 (t)}]E[exp{−Z exp(xα)H0 (t)}]}.
By Cauchy-Schwarz inequality we know that
E 2 [Z exp{−Z exp(xα)H0 (t)}]
= E 2 [Z exp{−Z exp(xα)H0 (t)/2} · exp{−Z exp(xα)H0 (t)/2}]
≤ E[Z 2 exp{−Z exp(xα)H0 (t)}]E[exp{−Z exp(xα)H0 (t)}].
Therefore, when α < 0,

∂
E[Z|D
∂x

≥ t, x] ≥ 0, which means that E[Z|D ≥

t, x] is non-decreasing in x. Similarly, when α > 0,

∂
E[Z|D
∂x

≥ t, x] ≤ 0,

which means that E[Z|D ≥ t, x] is non-increasing in x. Obviously, E[Z|D ≥
t, x = 1] ≥ E[Z|D ≥ t, x = 0] when α < 0; E[Z|D ≥ t, x = 1] ≤ E[Z|D ≥
t, x = 0] when α > 0.
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Figure 1. Misleading result from adjusted rate functions. (a) Survival
functions for death; (b) rate functions for recurrent diseases; and (c) adjusted
rate functions (——, the new drug; − − − , the existing drug).
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Figure 2. Adjusted rate and logarithm of adjusted rate ratio, λ0 (t) = 1/10,
h0 (t) = t/400, Z ∼ gamma (mean=10, variance=50).
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Figure 3. Survivors’ rate and logarithm of survivors’ rate ratio, λ0 (t) =
1/10, h0 (t) = t/400, Z ∼ gamma (mean=10, variance=50).
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Figure 4. Kaplan-Meier estimates of the survival function for death from
CPCRA ddI/ddC data (——, ddI; − − −, ddC).
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Figure 5. Estimates of three types of cumulative rate function for recurrent
events from CPCRA ddI/ddC data. (a) Cumulative rate function; (b) adjusted cumulative rate function; and (c) survivors’ cumulative rate function
(——, ddI; − − −, ddC).
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Table 1
Rate functions and proportional rate models

Rate

Definition
λ(t)dt = E[dN (t)]

Adjusted rate
Survivors’ rate

λA (t)dt = E [I(D ≥ t)dN (t)]
λS (t)dt = E[dN (t)|D ≥ t]

Model
λ(t|x, z) = zλ0 (t) exp(xβ)
h(t|x, z) = zh0 (t) exp(xα)
A
λA (t|x) = λA
0 (t) exp(xβ )
S
λS (t|x) = λS0 (t) exp(xβ )
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